



Based on Form PTO-99 (3/90) <b>PATENT &amp; TRADEMARK OFFICE</b> LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 678503-2005.1	SERIAL NO. 10/624,317
	APPLICANT Korokhov et al.	
	FILING DATE July 22, 2003	GROUP 1635 <b>1636</b>

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA						
AB						

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
AC							
AD							

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>was</i>	AE	Altman et al., Phenotypic analysis of antigen-specific T lymphocytes. Science 274:94-6 (1996).
<i>was</i>	AF	Belousova et al., Modulation of adenovirus vector tropism via incorporation of polypeptide ligands into the fiber protein. J Virol. 76:8621-31 (2002).
<i>was</i>	AG	Chartier et al., Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J Virol. 70:4805-10 (1996).
<i>was</i>	AH	Dmitriev et al., Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells. J Virol. 74:6875-84 (2000).
<i>was</i>	AI	Graham and Prevec, Methods for construction of adenovirus vectors. Mol. Biotechnol. 3:207-20 (1995).
<i>was</i>	AJ	Heiser et al., Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin. Invest. 109:409-17 (2002).
<i>was</i>	AK	Hong and Engler, Domains required for assembly of adenovirus type 2 fiber trimers. J Virol. 70:7071-8 (1996).
<i>was</i>	AL	Krasnykh et al., Genetic targeting of adenovirus vector via replacement of the fiber protein with the phage T4 fibrin. J. Virol. 4176-4183 (2001).
<i>was</i>	AM	Krasnykh et al., Genetic targeting of adenoviral vectors. Mol. Ther. 1:391-405 (2000).
<i>was</i>	AN	Krasnykh et al., Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob. J Virol. 72:1844-52 (1998).
<i>was</i>	AO	Krasnykh et al., Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J Virol. 70:6839-46 (1996).
<i>was</i>	AP	Krasnykh and Douglas, Targeted adenoviral vectors I: Transductional targeting. In Curiel and Douglas ed., Adenoviral Vectors for Gene Therapy. Academic Press, San Diego (2002).
<i>was</i>	AQ	Lo et al., High level expression and secretion of Fc-X fusion proteins in mammalian cells. Protein Eng. 11:495-500 (1998).
<i>was</i>	AR	Lodge et al., Expression and purification of prostate-specific membrane antigen in the baculovirus expression system and recognition by prostate-specific membrane antigen-specific T cells. J Immunother. 22:346-55 (1999).
<i>was</i>	AS	Meidenbauer et al., Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer. Prostate 43:88-100 (2000).
<i>was</i>	AT	Pereboev et al., Coxsackievirus-adenovirus receptor genetically fused to anti-human CD40 scFv enhances adenoviral transduction of dendritic cells. Gene Ther. 9:1189-93 (2002).

EXAMINER

*was accepted*

DATE CONSIDERED

10-4-2005

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Based on Form PTO-1449 (3/90) LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)				ATTY. DOCKET NO. 678503-2005.1		SERIAL NO. 10/624,317	
				APPLICANT Karokhov et al.			
				FILING DATE July 22, 2003		GROUP 1645 1636	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AU						
	AV						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES      NO
	AW						
	AX						
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
was	AY		Salgaller et al., Dendritic cell-based immunotherapy of prostate cancer. Crit. Rev. Immunol. 18:109-19 (1998).				
was	AZ		Tasch et al., A unique folate hydrolase, prostate-specific membrane antigen (PSMA): a target for immunotherapy? Crit. Rev. Immunol. 21:249-61 (2001).				
was	BA		Tillman et al., Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model. Cancer Res. 60:5456-63 (2000).				
was	BB		Tillman et al., Maturation of dendritic cells accompanies high efficiency gene transfer by a CD40-targeted adenoviral vector. 5 J Immunol. 162:6378-83 (1999).				
was	BC		Tjoa and Murphy, Progress in active specific immunotherapy of prostate cancer. Semin. Surg. Oncol. 18:80-7 (2000).				
was	BD		Von Seggern et al., Adenovirus vector pseudotyping in fiber-expressing cell lines: improved transduction of Epstein-Barr virus-transformed B cells. J Virol. 74:354 (1999)				
was	BE		Zou et al., Macrophage-derived dendritic cells have strong Th1-polarizing potential mediated by beta-chemokines rather than IL-12. J Immunol. 165:4388 (2000)				
was	BF		Zou et al., Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med. 7:1339 (2001)				
	BG						
	BH						
	BI						
	BJ						
	BK						
	BL						
	BM						
EXAMINER <i>was chlapkoll</i>				DATE CONSIDERED 10-04-2005			
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							